For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Mission Therapeutics Limited

USPTO Granted Patents = 34

% Expired Patents = 2.9

EPO Patents = 21

Forward Citations = 32

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Mark Kemp (31 out of 46 patents)

Martin Stockley (29 out of 34 patents)

Alison Jones (20 out of 26 patents)

4. Andrew Madin (14 out of 52 patents)

5. Karl Richard Gibson (12 out of 25 patents)

6. Gavin Alistair Whitlock (12 out of 32 patents)

7. Michael David Woodrow (10 out of 10 patents)

8. Xavier Jacq (2 out of 2 patents)

9. Christopher Andrew Luckhurst (2 out of 2 patents)

10. Paul William Thompson (2 out of 2 patents)

11. Stephen Philip Jackson (1 out of 18 patents)

12. Helen Robinson (1 out of 1 patent)

13. Yaara Ofir-Rosenfeld (1 out of 1 patent)

14. Paul Wijnhoven (1 out of 1 patent)

15. Ryotaro Nishi (1 out of 1 patent)

Core Competencies:

USP30 Inhibitors

DUB Inhibitors

Cyanopyrrolidines

Pyrrolidine Derivatives

Cancer Treatment

Isopeptidase Activity

Mitochondrial Dysfunction

Fibrosis

Deubiquitylating Enzymes

Heterocycles

Screening Methods

34 patents: Sort by Forward Citations

1. 12679833 - N-cyanopyrrolidines with activity as USP30 inhibitors (2026-07-14),

2. 12655152 - 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1H)-carbonitrile as USP30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis (2026-06-16),

3. 12637426 - 1-cyano-pyrrolidine compounds as USP30 inhibitors (2026-05-26),

4. 11993595 - Compounds (2024-05-28),

5. 11958833 - Compounds (2024-04-16),

6. 11945797 - 1-cyano-pyrrolidine derivatives as dub inhibitors (2024-04-02),

7. 11472798 - Compounds (2022-10-18),

8. 11414402 - Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors (2022-08-16),

9. 11390584 - 1-cyano-pyrrolidine compounds as USP30 inhibitors (2022-07-19),

10. 11370784 - Cyano-substituted heterocycles with activity as inhibitors of USP30 (2022-06-28),

11. 11352339 - 1-cyano-pyrrolidine derivatives as DUB inhibitors (2022-06-07),

12. 11319287 - Cyanopyrrolidines as dub inhibitors for the treatment of cancer (2022-05-03),

13. 11306096 - 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer (2022-04-19),

14. 11236092 - Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors (2022-02-01),

15. 11130748 - Compounds (2021-09-28),

Company Overview

Mission Therapeutics Limited is a biotechnology company based in Cambridge, UK, specializing in the development of innovative therapeutics targeting deubiquitylating enzymes (DUBs). The company focuses on advancing treatments for various diseases, including neurodegenerative disorders and cancer, by harnessing the potential of DUB inhibition. Mission Therapeutics aims to address significant unmet medical needs through its proprietary drug discovery platform, fostering collaborations to enhance its research and development efforts.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

34 Patents

#30 in Cambridge

#527 in United Kingdom

#19,631 in the World

Cambridge, United Kingdom

Mission Therapeutics Limited

Forward Citations = 32

15 inventors:

Mark Kemp (31 out of 46 patents)

Martin Stockley (29 out of 34 patents)

Alison Jones (20 out of 26 patents)

4. Andrew Madin (14 out of 52 patents)

5. Karl Richard Gibson (12 out of 25 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mission Therapeutics Limited. Retrieved from https://idiyas.com/company/mission-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…